In the world of biotech, effective communications are more than just a tool—it’s a lifeline. Early-stage biotech companies often face the daunting task of explaining complex science while vying for attention in a crowded market. Yet, it all begins with a clear and distinct message. Through our work at Russo Partners, we believe the key is to communicate not just what you do but why it matters in a way that resonates beyond the walls of the lab.
For preclinical life science companies, clarity is paramount. Your message must articulate your mission and goals succinctly. It’s not enough to say that you’ve enrolled your first patient in a trial or that you’re attending an investor conference. What’s more compelling is the data behind your progress—the tangible steps you’ve taken toward bringing promising treatments to the market. Establishing credibility is a process driven by data, and biotech companies must lean on this to build trust with investors, the scientific community, and regulators.
Building Your Core Messages
Before any biotech company can effectively communicate, it must first define its core message in a sentence or two and ensure it embodies the company’s vision.
To help articulate your core messages, you need to ask probing questions to internal and external stakeholders, including C-suite executives, investors, and other key opinion leaders (KOLs). Think of it as conducting stakeholder audits. What do these other parties need to understand? What do they expect from your organization in terms of success? Once you have this input, it helps position the company where it will make the most impact. Constant feedback from investors, scientists, and regulators can also help you steer the narrative during turbulent times. A strong core narrative aligns with both your mission and the expectations of your stakeholders. This is the cornerstone of a successful communications strategy.
Adapting and evolving
Sometimes, biotech companies find themselves in a quiet period—no big news to announce but the need for visibility persists. This is where thought leadership becomes a game-changer. CEOs and other executives should seize the opportunity to discuss broader industry trends, regulatory shifts, or innovations shaping the future of healthcare. It’s essential to step beyond company-specific news and engage within the broader ecosystem of biotech, AI, and healthcare. This positions companies and their executives as industry leaders, even during periods without new research to announce.
A partner to guide you through these quiet periods can help keep your organization top of mind. Panel discussions, publishing articles, and maintaining a strong media presence are just some of the key strategies we encourage. But remember, the focus should be on industry trends, not just your company’s narrative.
Moreover, communications are never static—biotech companies evolve, and so should your communications strategies. At Russo Partners, we recommend regular evaluations of websites, slide decks, and dissemination messaging in social and other media channels. Quarterly reviews allow companies to adjust their strategies based on engagement metrics, social media interactions, and competitive shifts. Whether it’s declining web traffic or new feedback from stakeholders, these indicators signal when it’s time for a change.
Striking the Balance Between Communications and Hype
Biotech communications are a balancing act. You want to showcase your achievements without exaggerating your accomplishments. Transparency and honesty should always be at the forefront of any communications effort. Stakeholders need to trust that you’re presenting accurate data and realistic expectations. This is why we often encourage biotech companies to seek third-party validation from KOLs, ensuring that your claims are credible and not overstated.
At the end of the day, every biotech company needs a strategic communications plan. This includes partnerships with external consultants who understand the pulse of the industry and can help navigate the complexities of the biotech community. Relationships are critical—whether it’s with investors, media, or industry leaders. This is why having a well-thought-out communications strategy is essential to building credibility in a market that demands innovation and transparency.
If you need help navigating these complex waters, partnering with a team that understands the industry’s pulse can make all the difference. At Russo Partners, we start the conversations that matter by not only helping you craft your message but also ensuring it resonates with the audiences that matter—all while keeping your company on track for success.
About the Author
Tony Russo, Ph.D., is Chairman and CEO of Russo Partners, a strategic communications firm serving biopharma, medtech, and digital health leaders for more than 35 years.
